Related Experiment Video

Updated: Aug 5, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Molecular docking analysis of the interaction between metformin/glimepiride combination and organic cation

Haneen A Mohammed1, Ekhlass M Taha1, Amaal S Sadiq1

  • 1DEPARTMENT OF CHEMISTRY, COLLEGE OF SCIENCE FOR WOMEN, UNIVERSITY OF BAGHDAD, BAGHDAD, IRAQ.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|July 31, 2026
PubMed
Abstract

Insights

Glimepiride/metformin effectively binds to organic cation transporter 1 (OCT-1), demonstrating its potential for managing type 2 diabetes and controlling blood glucose levels.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Molecular Biology

Background:

  • Organic cation transporter 1 (OCT-1) plays a role in drug transport and glucose metabolism.
  • Understanding drug-transporter interactions is crucial for optimizing therapeutic efficacy.

Purpose of the Study:

  • To investigate the interaction between glimepiride/metformin and OCT-1 using molecular docking.
  • To compare serum OCT-1 levels in type 2 diabetes patients and healthy individuals.

Main Methods:

  • Molecular docking simulations were performed to assess glimepiride/metformin binding to OCT-1.
  • Enzyme-linked immunosorbent assay (ELISA) was used to quantify serum OCT-1 levels in 50 women (26 with type 2 diabetes, 24 controls).

Main Results:

  • Molecular docking revealed a strong binding affinity (-10.2 kcal/mol) between glimepiride/metformin and OCT-1.
  • Serum OCT-1 levels were comparable between type 2 diabetes patients and healthy controls, suggesting efficient cellular uptake of the drug.

Conclusions:

  • The glimepiride/metformin combination exhibits significant interaction with OCT-1.
  • This interaction supports the use of glimepiride/metformin for effective blood glucose control in type 2 diabetes.
Keywords:
glimepiridemolecular dockingorganic cationtype 2 diabetes

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...